Literature DB >> 8807569

1,25-dihydroxyvitamin D3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats.

M Denda1, J Finch, A J Brown, Y Nishii, N Kubodera, E Slatopolsky.   

Abstract

Decreased content of the 1,25-dihydroxyvitamin D3 receptor (VDR) in parathyroid glands from patients and animals with chronic renal failure has been implicated in the pathogenesis of secondary hyperparathyroidism. In these studies, we examined the regulation of VDR by 1,25-dihydroxyvitamin D3 (1,25-D3) and 22-oxacalcitriol (OCT) in parathyroid glands of uremic rats. After eight weeks of renal failure, VDR content in parathyroid glands of uremic rats was decreased (400 +/- 42 vs. 729 +/- 47 fmol/mg protein in normal control rats, P < 0.05) and strongly correlated with serum 1,25-D3 levels (r = 0.829, P = 0.0001). Treatment with either 1,25-D3 or OCT prevented the decrease in VDR. We conclude that low serum 1,25-D3 levels, at least in part, account for the decrease in VDR content in parathyroid glands of uremic rats and that treatment with 1,25-D3 or OCT prevents this decrease ameliorating the development of secondary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807569     DOI: 10.1038/ki.1996.283

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

Review 1.  Vitamin D and its analogs in chronic renal failure.

Authors:  E Slatopolsky; A J Brown
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

2.  NF-κB activation contributes to parathyroid cell proliferation in chronic kidney disease.

Authors:  Sen Kan; Weichen Zhang; Jianping Mao; Mengjing Wang; Li Ni; Minmin Zhang; Qian Zhang; Jing Chen
Journal:  J Nephrol       Date:  2018-08-31       Impact factor: 3.902

Review 3.  Are new vitamin D analogues in renal bone disease superior to calcitriol?

Authors:  Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2005-02-03       Impact factor: 3.714

4.  Levels of vitamin D receptor and CYP24A1 in patients with end-stage renal disease.

Authors:  Jia-Jun Ye; Tian-Biao Zhou; Yun-Fang Zhang; Qi Wang; Yan-Yan Su; Jia-Min Tang; Hong-Yan Li
Journal:  Afr Health Sci       Date:  2016-06       Impact factor: 0.927

5.  Molecular and morphological approach of uremia-induced hyperplastic parathyroid gland following direct maxacalcitol injection.

Authors:  Kazuhiro Shiizaki; Ikuji Hatamura; Eiko Nakazawa; Manabu Ogura; Takahiro Masuda; Tadao Akizawa; Eiji Kusano
Journal:  Med Mol Morphol       Date:  2008-07-01       Impact factor: 2.309

Review 6.  Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment.

Authors:  Cheryl P Sanchez
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 7.  The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease.

Authors:  Ladan Zand; Rajiv Kumar
Journal:  Endocrinol Metab Clin North Am       Date:  2017-09-29       Impact factor: 4.741

Review 8.  Parathyroid Cell Proliferation in Secondary Hyperparathyroidism of Chronic Kidney Disease.

Authors:  Tally Naveh-Many; Oded Volovelsky
Journal:  Int J Mol Sci       Date:  2020-06-18       Impact factor: 5.923

Review 9.  Parathyroid Hormone Measurement in Chronic Kidney Disease: From Basics to Clinical Implications.

Authors:  Kittrawee Kritmetapak; Chatlert Pongchaiyakul
Journal:  Int J Nephrol       Date:  2019-09-17

10.  Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth.

Authors:  Masatomo Taniguchi; Masanori Tokumoto; Kazuhiko Tsuruya; Hideki Hirakata; Mitsuo Iida
Journal:  Nephrol Dial Transplant       Date:  2008-05-30       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.